Pancreatic Cancer Research

ResearcherUniversity of British ColumbiaActive in the last 2 years

Janel L. Kopp

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1875-3401; OpenAlex author ID A5086398659. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
37
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: 2 papers · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: 2 papers · 2024: none · 2025: none · 2026: 2 papers

Papers 12

  1. DNA methylation-based classification uncovers acinar and ductal origins for KPC-derived PDAC cell lines. Co-author DOI 10.1016/j.canlet.2026.218666↗
  2. Endogenous insulin mediates dynamic coordination between pancreatic cancer and systemic metabolism Last author DOI 10.64898/2026.08.26.745597↗
  3. Hyperinsulinemia acts via acinar insulin receptors to initiate pancreatic cancer by increasing digestive enzyme production and inflammation. Last author DOI 10.1016/j.cmet.2023.10.003↗
  4. Islet amyloid polypeptide does not suppress pancreatic cancer. Co-author DOI 10.1016/j.molmet.2023.101667↗
  5. Cell Type of Pancreatic Ductal Adenocarcinoma Origin: Implications for Prognosis and Clinical Outcomes. Last author DOI 10.1159/000520946↗
  6. Effects of hyperinsulinemia on pancreatic cancer development and the immune microenvironment revealed through single-cell transcriptomics. Last author DOI 10.1186/s40170-022-00282-z↗
  7. Deletion of pancreas-specific miR-216a reduces beta-cell mass and inhibits pancreatic cancer progression in mice. Co-author DOI 10.1016/j.xcrm.2021.100434↗
  8. Endogenous Hyperinsulinemia Contributes to Pancreatic Cancer Development. Co-author DOI 10.1016/j.cmet.2019.07.003↗
  9. Cell of origin affects tumour development and phenotype in pancreatic ductal adenocarcinoma. Last author DOI 10.1136/gutjnl-2017-314426↗
  10. Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma. Co-author DOI 10.1038/nature17988↗
  11. New insights into the cell lineage of pancreatic ductal adenocarcinoma: evidence for tumor stem cells in premalignant lesions? Co-author DOI 10.1053/j.gastro.2013.11.023↗
  12. Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ccr.2012.10.025↗

Closest collaborators

The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. David F. Schaeffer · 6 shared papers, 2019–2026 · strength 0.92
  2. James D. Johnson · 5 shared papers, 2019–2026 · strength 0.81
  3. Shilpa Patil · 2 shared papers, 2022–2023 · strength 0.41
  4. Jeffrey S.H. Lin · 2 shared papers, 2023–2026 · strength 0.39
  5. Anni M.Y. Zhang · 3 shared papers, 2019–2023 · strength 0.37
  6. Maike Sander · 4 shared papers, 2012–2019 · strength 0.27
  7. Mario A. Shields · 1 shared paper, 2026 · strength 0.24
  8. Seth J. Parker · 1 shared paper, 2026 · strength 0.24
  9. Rémy Nicolle · 1 shared paper, 2026 · strength 0.24
  10. Sofia Ferreira · 1 shared paper, 2026 · strength 0.24
  11. Ilianna Zoi · 1 shared paper, 2026 · strength 0.24
  12. Marc P. Stemmler · 1 shared paper, 2026 · strength 0.24
  13. Malak Haidar · 1 shared paper, 2026 · strength 0.24
  14. Ben Z. Stanger · 1 shared paper, 2026 · strength 0.24
  15. Daniel John Renouf · 1 shared paper, 2026 · strength 0.24
  16. Laura D Attardi · 1 shared paper, 2026 · strength 0.24
  17. Patrick Jacquemin · 1 shared paper, 2026 · strength 0.24
  18. Austin J. Taylor · 1 shared paper, 2023 · strength 0.19
  19. C. Bruce Verchere · 1 shared paper, 2023 · strength 0.19
  20. Hong Li · 1 shared paper, 2022 · strength 0.13
  21. Alex Y.L. Lee · 1 shared paper, 2019 · strength 0.11
  22. Marina Lesina · 1 shared paper, 2021 · strength 0.10
  23. Stephan Herzig · 1 shared paper, 2021 · strength 0.10
  24. Süheda Erener · 1 shared paper, 2021 · strength 0.10
  25. Timothy J. Kieffer · 1 shared paper, 2021 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.